SCHEMBL30855205

SCHEMBL30855205

CC(C)(C)OC(=O)N1CCOC[C@H]1c1cc(Cl)cc(-c2ccnc(N)c2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UCHL1 P09936 1/20 0.41
▸ MALT1 Q9UDY8 1/20 0.39
▸ PIK3CA P42336 8/20 0.37
▸ PIK3R1 P27986 7/20 0.37
▸ USP7 Q93009 1/20 0.36
▸ TBK1 Q9UHD2 1/20 0.36
▸ MTOR P42345 2/20 0.35
▸ ATR Q13535 2/20 0.35
▸ PDCD1 Q15116 2/20 0.35
▸ CD274 Q9NZQ7 2/20 0.35
▸ CHEK1 O14757 1/20 0.35
▸ ATRIP Q8WXE1 1/20 0.35
▸ CCNC P24863 1/20 0.35
▸ CDK8 P49336 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29333868 1.00 UCHL1 (0.41) UCHL1MALT1PIK3CAPIK3R1USP7
SCHEMBL22726571 0.85 UCHL1 (0.41) UCHL1MALT1PIK3CAPIK3R1MTOR
SCHEMBL29953613 0.85 UCHL1 (0.41) UCHL1MALT1PIK3CAPIK3R1MTOR
SCHEMBL30855103 0.85 MALT1 (0.40) UCHL1MALT1PIK3CAPIK3R1CCNC
SCHEMBL29334162 0.85 MALT1 (0.40) UCHL1MALT1PIK3CAPIK3R1CCNC
SCHEMBL29333870 0.84 NR1H2 (0.42) MALT1CCNCCDK8TSHRUSP30
SCHEMBL29333832 0.84 NR1H2 (0.42) MALT1CCNCCDK8TSHRUSP30
SCHEMBL30855178 0.83 BTK (0.36) PIK3CAUSP7MTORATRPDCD1
SCHEMBL29333566 0.83 BTK (0.36) PIK3CAUSP7MTORATRPDCD1
SCHEMBL29333891 0.83 MALT1 (0.37) MALT1PIK3CAPIK3R1MTORATR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4594308-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF Vividion Therapeutics, Inc. (US) 2025-08-06 — — EP disclosed
US-20240226114-A1 INHIBITORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. 2024-07-11 — — US disclosed
WO-2024073587-A1 N-ACRYLOYLMORPHOLINE DERIVATIVES AS KEAP1 MODULATORS AND USES THEREOF VIVIDION THERAPEUTICS, INC. (US) 2024-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226114-A1 INHIBITORS AND USES THEREOF KEAP1, NQO1, NFE2L2 UCHL1 2968/4885MALT1 4516/4885PIK3CA 3512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback